Skip to main content

Advertisement

Fig. 6 | Genome Medicine

Fig. 6

From: Integrative omics analyses broaden treatment targets in human cancer

Fig. 6

Integrative omics analysis of druggability. a TCGA tumor samples are sorted by completeness of DNA/RNA/protein profiling, number of variant types supporting druggability, number of drug classes, and number of druggable genes. Of the 3121 tumor samples with complete profiling, 1003 are potentially druggable based on > 1 variant types (mutational, RNA expression, protein expression) and are represented in b. b Multi-drug and multi-omic relationships within tumor samples. Ten outer sectors separate samples according to biomarkers associated with sensitivity to one of ten FDA-approved drug classes. Each outer sector consists of three tracks: DNA mutation (inner), RNA expression (middle), and protein expression (outer). Different colored bands within these tracks represent different genes whose variants implicate druggability in a single tumor sample. The genes represented in each sector vary according to drug class; adjacent to each sector is a legend indicating represented genes. The total number of unique samples is labeled under each sector. A gray link (between wedges) represents a single tumor with biomarkers associated with sensitivity to multiple drug classes. A green link (within a wedge) represents a single tumor with multiple biomarkers of the same variant type associated with sensitivity to a single drug class (e.g., a single tumor with RNA expression in ESR1 and PGR)

Back to article page